Coherus BioSciences (CHRS +14%) is up on increased volume following better-than-expected Q2 results released after the close yesterday.
Sales of its Neulasta biosimilar, UDENYCA (pegfilgrastim-cbqv) were $83.4M, up 125% from Q1. U.S. market share is now ~13% and could reach 20% by year-end.
Net income was up 154% to $23.6M while EPS was up 147% to $0.32.
Key pipeline candidates include biosimilars to AbbVie’s Humira, Amgen’s Enbrel, Roche’s Lucentis and Regeneron’s Eylea.
It expects to initiate a NASH program later this year.
Previously: Coherus BioSciences EPS beats by $0.07, beats on revenue(Aug. 1)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.